EXCLUSIVE-NETWORKS
3.3.2021 10:02:11 CET | Business Wire | Press release
Exclusive Networks, the global trusted digital infrastructure specialist, today announced its appointment of international channel veteran Denis Ferrand-Ajchenbaum to lead its global vendor strategy. A highly knowledgeable channel leader, Denis brings a proven scorecard of vendor success to his role where he will be responsible for maximising the value and global penetration of existing vendor relationships while scouting and acquiring the next generation of Exclusive Networks’ trust digital infrastructure portfolio. The ex-Arrow and IBM senior executive brings over 30 years’ leadership experience and extensive C-level connections gleaned from his Silicon Valley background and presence across technology forums.
“Our choice of vendors, and the relationships we have with them, is a keystone of the Exclusive Networks proposition and we believe there is significant additional value to come from implementing a strategy aligned to our trusted digital infrastructure mission,” said Jesper Trolle, CEO of Exclusive Networks. “Denis has exactly the right skills and experience to strengthen and harmonise our blend of vendor alliances, bringing huge growth opportunities to all our partners around the world. Having worked alongside him for many years, I am confident that Denis will hit the ground running and play a pivotal role in our future success.”
Denis Ferrand-Ajchenbaum has spent his entire career in enterprise IT, more than 20 years of which at value-added distributors on a national, regional and global scale. He joins Exclusive Networks from Arrow where his roles included leading global vendor management, developing EMEA product strategy, shaping its ‘advanced technology group’ vendor incubation business unit and, most recently, as VP Sales of its Arrowsphere cloud delivery platform. His other experience – in a variety of business development and sales positions – includes stints at IBM, Avnet and Clearpoint.
“I’m delighted to join Exclusive Networks as we embark on a new mission to enable a totally trusted world for people and organisations,” said Denis Ferrand-Ajchenbaum. “Our success to date has been a story of always being different in order to maintain momentum and keep our value model intact. We now need to consolidate and expand our global specialism in trusted digital infrastructure by filling out all market segments related to this, continuing to drive innovation and investing in our alliances with both existing and new vendor partners. The vendor landscape is multilayered and very fast moving, and I look forward to working closely with our vendor community and bringing them more closely together; enabling new opportunities through cross-selling and upselling, new consumption models, high-value services and greater global coordination.”
-ends-
About Exclusive Networks
Exclusive Networks Exclusive Networks is the global trusted digital infrastructure specialist driving the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models.
The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to outstrip market growth. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. More at www.exclusive-networks.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
